ALNA - Allena Pharmaceuticals: Unique Treatment For Enteric Hyperoxaluria Not Reflected In Valuation
Allena Pharmaceuticals (ALNA) is focused on rare metabolic and kidney disorders. Its lead drug, Reloxiliase, degrades oxalate in the gastrointestinal tract, and is being studied to treat enteric hyperoxaluria (EH). EH is a form of secondary hyperoxaluria that can cause nephrolithiasis (kidney stone formation) and nephrocalcinosis, and it contributes to chronic kidney disease. Reloxiliase is currently in Phase 3 clinical studies, and topline data from the URIROX-1 trial is slated to be reported before the end of the year. Topline data from the longer URIROX-2 study will be reported in 2021.